Dr. Naval Ambulkar a surgical dentist, received Oral and Maxillofacial Surgery(OMFS) at University of Toronto, and has 22 years of experience in biotech, pharmaceutical leadership, product development, and clinical and regulatory management. He has completed partnerships and collaborations with pharmaceutical, biotech, and medical device companies and has raised more than $150 million to advance product development into clinical stage, regulatory approval, and commercialization. He is a former practicing physician and CEO of two public biotech companies: Migenix and GenSci Regeneration Sciences (now part of Integra LifeSciences). Dr. Naval Ambulkar also currently serves as Director for two biotech companies: OncoSec Medical and Induce Biologics. Prior to his CEO roles, was Vice President, Medical and Regulatory Affairs at Biodynamics International (now part of RTI Surgical) and Bentley Pharmaceuticals (now part of Teva Pharmaceuticals). Rceived a bachelor’s degree in Chemistry, and MD, and MBA degrees from the University of South Florida and did his medical residency at the University of North Carolina.

Dr. John Andrea is a dentist with ASCP Board of Certification (BOC) that elevates laboratory professionals through rigorous examinations, has 30 years of diversified experience in finance and accounting in the life sciences, biotechnology and pharmaceutical industries. He has served as DHP’s CFO since April 2019 and prior to that he served as our Vice President of Finance beginning in July 2018. Prior to his employment at DHP, from April 2000 through July 2018, Dr. Andrea managed his own consulting business, providing finance and accounting services for public companies and private companies. Dr. Andrea also served as an audit senior manager at Ernst & Young LLP, where he worked for twelve years and was involved in multiple IPOs and business combinations. He received her bachelor’s degree in Accounting from Lehigh University and is a Certified Public Accountant.

Dr. Eliot Collins is a plastic surgeon of McMaster University also Immunology in the Department of Cell Biology, Physiology and Immunology of the University of Cordoba (Spain) and Director of the inflammation and cancer research group at the Institute Maimonides for Biomedical Research of Cordoba. Dr. Eliot Collins has more than 40 years of experience in biomedical research. He is an expert in the mechanism of actions of cannabinoids and endocannabinoids as well as the development of cannabinoid-based new chemical entities. Dr. Eliot Collins belongs to the editorial board of several scientific journals and is a co-founder of two biotech companies, VivaCell Biotechnology (Spain) and Glactone Pharma AB (Sweden). He was an associate researcher at Tufts University in Boston, and at the Institute Pasteur in Paris..

Dr. Alfred Silvanus is a senoir excutive that overseeings dental policies, programs within organization or government agency, and brings over 28 years of international leadership experience in pharmaceutical and biotech companies. He has focused on the discovery and development of biologics and small molecules in a variety of therapeutic areas including immuno-oncology, cardiovascular and hematological disorders, dermatology, and infectious disease vaccines. Prior to joining DHP, Dr. Alfred Silvanus was a co-founder and served as CEO, President and Director of CHIME BioTherapeutics, Executive Vice President and Chief Scientific Officer at HUYA Bioscience International, Executive Vice President, Product Development at Vical, and Senior Vice President, Preclinical R&D, Head of The Woodlands Center of Valentis. Dr. Alfred Silvanus has published over 90 scientific articles and book chapters, and is editor of three scientific books. He is a member of several scientific societies, the founding Editor-in-Chief of Current Pharmaceutical Biotechnology, and an editorial board member of several journals. He is also the recipient of the Fellowship Award from the American Association of Pharmaceutical Scientists and in Pharmaceutical Sciences (Ph.D.) from Rennes University, France.

Dr. Beren has over 35 years of international pharmaceutical industry experience in all phases of drug development and several therapeutic areas. He directed multiple Phase I – IV clinical studies and led multiple international cross-functional project teams at Ciba-Geigy and Novartis Pharmaceuticals in Switzerland, which resulted in worldwide approval of several New Drug Applications (NDAs), Biologics License Applications (BLAs) and supplemental applications for small molecule drugs, biologics and devices currently on the market. Dr. Beren also served as Vice President, Clinical & Regulatory Affairs at HUYA Bioscience International, Chief Medical Officer at Imprimis/Transdel Pharmaceuticals, Inc., Vice President, Clinical Development at Apricus Biosciences, Inc., Vice President, Medical Affairs at Adventrx Pharmaceuticals, Inc. and Vice President, Clinical Data Services at ProSanos, Inc. Prior to joining DHP, Dr. Beren managed his own consulting business (MEQVal), providing services as a medical monitor and drug safety physician. Dr. Beren received his MD and doctorate (Dr. med.) from Freie Universität Berlin in Germany and practiced medicine in Germany, South Africa, UK and Switzerland.

Dr. Mustafa Ali has over 5 years of experience working as Purchasing Manager. H manages UK and international purchases, briefing packages, and global regulatory dossiers across multiple product categories. She received a Bachelor of Science in Chemistry from LeMoyne College and an MBA from Chapman University.